N
NeuraLight
Developer of neurology software designed to help patients affected by neurological disorders
About NeuraLight
Neuralight.ai is a cutting-edge startup focused on revolutionizing the field of neurology through the use of artificial intelligence (AI). The company has developed an AI-driven platform designed to accelerate and enhance drug development, patient monitoring, and precision care for individuals with neurological disorders. By leveraging oculometric data—measurements related to eye movements—captured using a standard webcam, Neuralight.ai aims to provide early diagnosis, accurate monitoring, and personalized treatment plans for neurological conditions.
Read full description
The primary clients of Neuralight.ai include pharmaceutical companies, healthcare providers, and research institutions. These clients benefit from the platform's ability to identify novel biomarkers—biological indicators of disease—thereby improving the efficiency and effectiveness of clinical trials and patient care. The company operates in the healthcare and biotechnology markets, specifically targeting neurological disorders such as Alzheimer's Disease, Amyotrophic Lateral Sclerosis (ALS), and Multiple Sclerosis.
Neuralight.ai's business model revolves around offering its AI platform as a service. The company generates revenue through subscription fees, licensing agreements, and partnerships with pharmaceutical companies and healthcare providers. By providing a scalable and cost-effective solution, Neuralight.ai enables its clients to achieve better outcomes in drug development and patient care.
In summary, Neuralight.ai is transforming the landscape of neurology by digitizing the evaluation and treatment of neurological disorders. The company's innovative use of AI and oculometric data aims to improve the lives of over a billion people worldwide who suffer from these conditions.
Latest news
Press, funding announcements and product moves mentioning NeuraLight.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | May 2022 | $25M | $100M | Samsung Next · Lily Sarafan · Koch Disruptive Technologies · David Golan | ↗ |
| SEED✓Equity / VC | Oct 2021 | $5.5M | $22M | Noam Solomon · Operator Partners · VSC Ventures · Vivek Garipalli | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for NeuraLight is 4.7K monthly website visits, up 235.7% over the last three months. NeuraLight's team declined 19.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed7 investors entered at this stage
Noam Solomon
Operator Partners
VSC Ventures
Vivek Garipalli
Tuesday Capital
MS&AD Ventures
Kli Capital
Series A6 investors entered at this stage
Samsung Next
Lily Sarafan
Koch Disruptive Technologies
David Golan
Chris Mansi
Breyer Capital
Other known investors6 additional known investors
Alumni Ventures
Asaf Fybish
Fidji Simo
Gil Shklarski
Maxim Godin- OMOfer Maor
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about NeuraLight on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NeuraLight’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.